LONDON, UK / ACCESSWIRE / October 11, 2022 / Antisense Therapeutics is an Australian biotechnology company developing antisense oligonucleotide therapies for the treatment of rare diseases. Its lead asset, ATL1102, is being investigated as a targeted anti-inflammatory therapy to treat Duchenne muscular dystrophy (DMD). In a positive strategic pivot, trial design was amended to a smaller Phase IIb study (n=42 vs 108) that should provide a nearer-term catalyst, if positive readouts are achieved. As a result of the reduced trial costs, the company’s cash runway is anticipated to be extended (net cash at end-June 2022 of A$19.2m) into Q4 CY23. Management envisages a need to raise funds in the mid-single digit (A$m) region, which it anticipates will fund operations to trial readouts in Q124.
Management anticipates study sites to be initiated in Q422 for the Phase IIb multicentre, randomised, double-blind, placebo-controlled, open-label extension study to assess the efficacy and safety of ATL1102. Patients will be treated with either 25mg or 50mg per week of ATL1102, with advantages over existing corticosteroids that lack efficacy and often associated with unwanted side effects. In addition, Antisense is progressing the development of ATL1102 in limb girdle muscular dystrophy R2 and looking to exploit new IP it has generated using SomaScan, a bio-diagnostic platform, for the diagnosis and prognosis of neurological disorders in long COVID-19 patients.
Click here to view the full report or here to sign up to receive research as it is published.
All reports published by Edison are available to download free of charge from its website
About Edison: Edison is a leading research and investor relations consultancy, connecting listed companies to the widest pool of global investors. By focusing on the volume and quality of investors reached – across institutions, family offices, wealth managers and retail investors – Edison can create and gauge intent to purchase, even in the darkest pools of capital, and then make introductions via non-deal roadshows, events or virtual meetings.
Having been the first in-market 17 years ago, Edison now has more than 100 analysts covering every economic sector. Headquartered in London, Edison also has offices in New York, Frankfurt, Amsterdam and Tel Aviv and a presence in Athens, Johannesburg and Sydney.
Edison is authorised and regulated by the Financial Conduct Authority.
Edison is not an adviser or broker-dealer and does not provide investment advice. Edison’s reports are not solicitations to buy or sell any securities.
For more information, please contact Edison:
Soo Romanoff +44 (0)20 3077 5700: [email protected]
Dr Adam McCarter +44 (0)20 3077 5700: [email protected]
Learn more at: www.edisongroup.com and connect with Edison on:
LinkedIn: www.linkedin.com/company/edison-group-/|
Twitter: www.twitter.com/Edison_Inv_Res
YouTube: www.youtube.com/edisonitv
SOURCE: Edison Investment Research Limited
View source version on accesswire.com:
https://www.accesswire.com/719888/Antisense-Therapeutics-ANP-Breaking-the-Mould-in-DMD-treatment
Image and article originally from stocksnewsfeed.com. Read the original article here.